This suggests CCR5 antagonist treatment may be a promising approach to reduce tumor growth in other solid tumors in which CCL5 plays a pro-tumoral role, such as PCa, where Maraviroc was shown to reduce bone metastasis of intracardially injected PCa cells in mice (125). This evidence concerns the gene CCL5 and posterior cortical atrophy.